1 Growth Stock Down 40% to Buy and Hold Forever [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
The drugmaker's shares are down by 40% over the trailing-12-month period, despite grabbing headlines for its work in the red-hot weight management drug market. Novo Nordisk has faced some issues, but even taking those into account, the company's prospects remain excellent. Long-term investors can still safely add this stock to their portfolios and hold it for for the long term. Novo Nordisk's most famous GLP-1 medicines, Wegovy and Ozempic, are helping drive solid top-line growth. In 2024, the company's net sales increased by 25% year over year to 290.4 billion Danish kroner ($42 billion USD). That would be an excellent performance for most drugmakers of this size and would likely lead to a strong stock market performance for the year. How
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Lawsuit alleges Maryland man with diabetes became blind after taking Ozempic [MSNBC.com]MSNBC.com
- Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic [MSNBC.com]MSNBC.com
- Novo Nordisk protects US patients with legal wins against compounders, including ruling that permanently prohibits compounding pharmacy from selling illegitimate, knockoff Wegovy® or Ozempic® [Yahoo! Finance]Yahoo! Finance
- Ozempic compounders suffer fresh setback as judge rejects injunction [Seeking Alpha]Seeking Alpha
- Novo Nordisk A/S (NYSE: NVO) was downgraded by analysts at Dbs Bank to a "sell" rating.MarketBeat
NVO
Earnings
- 2/6/25 - Beat
NVO
Sec Filings
- 4/23/25 - Form SCHEDULE
- 4/3/25 - Form 6-K
- 3/31/25 - Form 6-K
- NVO's page on the SEC website